Latest NewsLifestyle & Health

Sputnik V : Serum Institute To Start Production of Sputnik V From September

Sputnik V : Serum Institute To Start Production of Sputnik V From September

From September, the Russian vaccine Sputnik V will be manufactured at Serum Institute of India’s manufacturing plants in Pune. The Russian RDIF (Russian Direct Investment Fund) said they “intend to produce over 300 million doses in India per year”. Technology transfer has already started and the first batch of vaccines is expected in September.

The first batch of Sputnik V vaccinations is planned to be produced at SII’s facilities in September, according to the official release. It plans to generate over 300 million vaccine doses per year in India.

“The parties intend to produce over 300 million doses of the vaccine in India per year with the first batch expected in September 2021,” the Russian Direct Investment Fund (RDIF) said in a statement.

SII, the world’s largest vaccine manufacturer by volume, has already received cell and vector samples from Russia’s Gamaleya Centre, RDIF said.

“With their import approved by the Drug Controller General of India (DCGI), the cultivation process has begun,” RDIF said in a statement.

“To date, the Russian Sputnik V vaccine has been registered in 67 countries globally with a total population of over 3.5 bn people. The data obtained by regulators of a number of countries during the vaccination of the population, including in Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE, and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus,” RDIF said.

“I am delighted to partner with RDIF to manufacture the Sputnik vaccine. We hope to make millions of doses in the coming months, with trial batches starting in September. With high efficacy and a good safety profile, it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world. Given the uncertainty of the virus, it is important for international institutes and governments to collaborate and further bolster up our fight against the pandemic,” Adar Poonawalla, CEO of Serum Institute of India, said in a statement.

Dr. NK Arora, the chairman of the National Expert Group on Vaccine Administration, is optimistic that the government will fulfill its December deadline.

ALSO READ :- New COVID Variant “Delta Plus Variant”: Everything you should know.

Gets all the latest updates on Latest NewsCoronavirus News and Entertainment News.